Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betalutin in Relapsed/Refractory DLBCL
NCT02658968Phase 1Completed
- Sponsor
- Nordic Nanovector ASA
- Start
- Mar 2017
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of lutetium (177Lu) lilotomab satetraxetan in diffuse large B-cell lymphoma (DLBCL), sponsored by Nordic Nanovector ASA. Primary endpoint: Number of Participants With Dose Limiting Toxicities to Determine the MTD at 12 weeks. Started Mar 2017; status: completed.
02
Drugs
lutetium (177Lu) lilotomab satetraxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02658968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02658968.